Sentences with phrase «therapy on cancer patients»

Not exact matches

The Food and Drug Administration (FDA) on Tuesday gave Swiss drug giant Novartis a second approval for its pioneering CAR - T cancer therapy, which uses patients» own immune cells (re-engineered outside the body and then replicated) to destroy blood cancers.

Basically, CAR - T therapy involves taking a patient's own immune «killer» T - cells, inserting new genetic code into those cells which turn them into cancer - hunters that can home in on malignant B - cells (another kind of immune cell), and then pumping these specialized leukemia - busting cells back into the patient.

The treatment is a type of so - called CAR T - cell therapy — taking a patient's own immune cells, called T cells, genetically manipulating them to attack specific proteins on cancer, and infusing them back into the patient.

His research has spanned hematopoiesis, gene therapy, stem cell biology, genomics and cancer, consistently focusing on bringing the very latest research advances to patients with heretofore incurable diseases.

«The US spends $ 90bn on cancer therapies annually and about 75 % of that fails to provide the intended clinical benefit of prolonged patient survival.»

Overcoming the immense logistical challenges involved with withdrawing, shipping, modifying, returning, then reinfusing cells for every patient treated paints a scary question mark on the future of cell - based cancer therapies.

There was also no change based on whether patients had undergone hormone therapy, a common treatment for prostate cancer which lowers the male hormone and can be combined with daily radiation.

During this in depth study, an international team of researchers led by British scientists investigated the impact of anti-hormone therapy on samples taken from patients with prostate cancer.

A transformative cancer therapy based on modified immune cells has lured doctors, companies, and patients alike, but many are hitting a frustrating roadblock: generating enough of these chimeric antigen receptor (CAR)- T cells to meet surging demand.

Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cCancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancercancer.

«Cervical cancer patients are currently treated as a uniform group based on chemotherapy and radiation regimens that help the largest percentage of people; however, one third of these patients are not helped by standard therapies,» Banister said.

The scientists also tested the therapy on tumors taken from two patients who had not responded to conventional therapy for their glioblastoma, a deadly form of brain cancer.

But success could leave a lasting mark on cancer care, by helping hundreds of thousands of patients every year, far more than other genetically targeted therapies.

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fightPatients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fightpatients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapies.

Finding a cure or a better therapy for cancer will relieve the burden on the patient's family, on the health system and society as well.

This method will facilitate the analysis of patient tumors and the selection of the most appropriate therapy based on the individualized features of each patient's cancer subtype.

«However, patients eventually experience progression of cancer on this treatment, highlighting the need for additional therapies.

He also plans a multicenter / multinational study of patients with melanoma or other types of cancer, to examine the effect of long - term CPAP therapy on those also diagnosed with sleep apnea.

Patients relying on lifesaving therapies for emergency care and cancer have long - suffered from stops and starts in drug manufacturing.

Chimeric antigen receptor (CAR) T - cell therapies utilize a patient's own T cells that have been genetically engineered to bind to a specific antigen on target cancer cells.

«Oncologists here at Moores Cancer Center at UC San Diego Health and elsewhere can often personalize cancer therapy based on an individual patient's unique cancer mutations,» said senior author Trey Ideker, PhD, professor of genetics at UC San Diego School of MedCancer Center at UC San Diego Health and elsewhere can often personalize cancer therapy based on an individual patient's unique cancer mutations,» said senior author Trey Ideker, PhD, professor of genetics at UC San Diego School of Medcancer therapy based on an individual patient's unique cancer mutations,» said senior author Trey Ideker, PhD, professor of genetics at UC San Diego School of Medcancer mutations,» said senior author Trey Ideker, PhD, professor of genetics at UC San Diego School of Medicine.

Patients with metastatic colorectal cancer (mCRC) that are mutation - free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first - line chemotherapy and an anti-EGFR monoclonal antibody, according to study results (1) presented today at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, cancer (mCRC) that are mutation - free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first - line chemotherapy and an anti-EGFR monoclonal antibody, according to study results (1) presented today at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Cancer in Barcelona, Spain.

HSCT is effectively used today as a form of «replacement» therapy for patients with hard - to - treat blood cancers, providing healthy cells from either the patient (autologous transplantation) or from a donor (allogeneic transplantation) to better equip patients to fight the disease on their own.

Commenting on the trial, Dr Alice Shaw, director of thoracic oncology at the Massachusetts General Hospital Cancer Centre in Boston, US, said: «This is the first randomised study to examine how a second generation ALK inhibitor compares to standard second line chemotherapy in ALK positive patients who failed the standard first line therapy, which currently is crizotinib.»

The researchers are now looking at how ICOS signals can be altered to diminish autoimmune disorders and augmented for more effective vaccine development, and are beginning research on how ICOS signaling may benefit Chimeric Antigen Receptor - T cell (CAR - T) therapies, which involves engineering of patient's own immune cells to recognize and attack their cancers.

Cancer researchers monitor circulating DNA carrying cancer - related mutations to follow patients» responses to targeted therapies and are working on similar tests for early signs of cCancer researchers monitor circulating DNA carrying cancer - related mutations to follow patients» responses to targeted therapies and are working on similar tests for early signs of ccancer - related mutations to follow patients» responses to targeted therapies and are working on similar tests for early signs of cancercancer.

Perhaps shedding light on this mystery, the researchers found three different types of mutations in the estrogen receptor in patients whose cancer was resistant to anti-hormone therapy.

Kathi Apostolidis, Vice President of The European Cancer Patient Coalition (ECPC) one of the partners on the eSMART project, said: «In many European countries, patients undergoing chemotherapy, experience great difficulties in coping with the adverse events and the anxiety during their therapy and between treatments.

For patients with difficult - to - treat cancers, doctors increasingly rely on genomic testing of tumors to identify errors in the DNA that indicate a tumor can be targeted by existing therapies.

Based on these results, two phase 3 trials are being planned for platinum - sensitive and platinum - resistant ovarian cancer patients by one of NCI's new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group cancer patients by one of NCI's new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).

His group focuses on understanding the underlying mechanisms that mediate cancer - inhibitory versus tumor - promoting inflammation, with the goal of designing new therapies for cancer patients.

In preliminary findings presented at the 2016 San Antonio Breast Cancer Symposium, researchers showed that older patients were as likely as younger patients to receive targeted therapy and enroll in therapeutic trials based on their sequencing results.

This is our dream for personalized cancer therapy, so we're not just guessing any more about which drugs will work but can choose drug targets based on what's driving that patient's cancer,» said Josh Stuart, the Baskin professor of biomolecular engineering at UC Santa Cruz, director of cancer and stem cell genomics at the UCSC Genomics Institute, and a senior corresponding author of the paper.

The scientists said that while most therapies are based on the on - size - fits - all model of medicine, «we've long recognized in cancer that every patient's tumor is different.

Hennekens and Bjorkman advise doctors that, based on the current totality of evidence, in the primary prevention of vascular disease and cancer, any judgments about prescribing long - term aspirin therapy for apparently healthy individuals should be based on individual clinical judgments between the doctor and each of his or her patients.

A new blood test using gold nanoparticles could soon give oncologists an early and more accurate prognosis of how cancer treatment is progressing and help guide the on - going therapy of patients.

ura Oncology Inc., a clinical stage biopharmaceutical company that develops therapies for cancer patients, is now trading on the NASDAQ after an initial public offering.

A randoMized phAse II trIal of fulvestraNt wiTh or without Ribociclib After progression on AntI-estrogeN therapy plus cyclin - dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (MAINTAIN Trial)

Repurposing approved and abandoned drugs for cancer represents an opportunity to rapidly advance to patients promising drug therapies by capitalizing on existing data and experience.

The data presented provide new insights on the potential mechanism by which Seres» microbiome therapies could improve the outcomes of cancer patients treated with immune checkpoint inhibitors.

It's only three patients on a low dose of cells, but San Diego - based Poseida said the results — activity against the cancer and no «cytokine storm» side effects that often come with CAR - T therapy — were good enough to step up to the next dose.

My translational research has focused on trying to find better ways to estimate recurrence risk in patients diagnosed with oestrogen - receptor positive early breast cancer, with the ultimate aim to better personalise our therapies for those patients who have the most to gain from them.

Assessment of Distress, Unmet Needs, and Receipt of Care Plans Among Cancer Survivors in Georgia: A Needs Assessment Cancer Survivorship in Georgia Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer Georgia's Cancer Survivorship Needs Survey Life After Cancer: Survivorship by the Numbers Resources for Health Care Professionals Survivorship Resources and Services

Our radiation oncologists and physicists are dedicated to ensuring that patients receive the very best radiation treatment based on their specific breast cancer diagnosis, recommended dosage, and the targeted body area receiving radiation therapy.

Radiation therapy is a lifesaver for patients with head and neck cancer, but the treatment takes a toll on the salivary gland.

Precision medicine clinical trials assign patients to therapy based on the genetic alterations that are thought to be driving their cancer.

This specificity in treatment fits with an emerging approach in cancer treatment nationwide, known as personalized medicine, in which the therapies for each patient are selected based on the genes altered in their tumors.

Heidi Simmons decided to focus on cell therapy for treatment of blood cancers like leukemia, lymphoma and myeloma, where healthy cells are infused into patients to replenish those damaged by cancer.

Research into immunotherapy, which cancer experts are calling the most promising approach in decades, got a boost Tuesday when Michael Bloomberg and other philanthropists announced $ 125 million in donations to Johns Hopkins University for a new institute focused solely on the therapy and accelerated breakthroughs for patients.